Lif calls for industry involvement to secure medicine supplies

Industry representatives from Lif argue that strengthening medicine preparedness requires leveraging the capabilities of the pharmaceutical industry rather than relying solely on public production. They highlight that global supply chains are increasingly vulnerable to crises and production disruptions.

The discussion follows the European Union’s Critical Medicines Act, which aims to build more resilient supply chains, increase diversification, and strengthen European production capacity to ensure patients have uninterrupted access to essential treatments.